Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MA Prior Auth Coverage Upda…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 433

    Formulary Exception / Non-covered Drug Prior Authorization

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 433 alerts

    Get alerted when Policy 433 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSMA prior authorization and formulary exception criteria for coverage of non-formulary or non-covered prescription drugs for commercial members under the BCBSMA formulary; excludes Medicare Advantage. Affects prescribers requesting coverage exceptions and pharmacy operations processing prior authorizations.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyFormulary Exception / Non-covered Drug Prior Authorization
    Policy CodePolicy 433
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionSubmit the Formulary Exception/Prior Authorization form to BCBSMA Pharmacy Operations to request coverage for non-formulary or non-covered drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    24 monthsLength of approval
    RxBenefit
    CommercialMember population
    ExcludedMedicare Advantage
    20+Therapeutic categories listed

    Formulary Exception and Non-covered Drug Coverage Criteria

    Formulary Exception / Non-covered Drug Coverage Criteria

    Covered when ANY of the following primary conditions are met, or when subsequent criteria are satisfied:

    Primary coverage pathways

    • Successful maintenance pathway: Provider establishes via documented clinical records or medication history that the Member has been successfully maintained on their current medication regimen and provides clinical justification that a change to a formulary alternative would result in instability of the medical condition.

      Documentation required to support reason for clinical justification

    • Device-dependent pathway: Member is actively using a medical device (for example, continuous subcutaneous insulin infusion pump) and requires the use of non-covered diabetic test strips.

      Documentation required

    Alternative and compendia criteria when not successfully maintained: If the Member is not successfully maintained per the primary pathways, ALL of the following must be met: the requested drug is for an FDA‑approved indication or an indication supported by recognized compendia or current treatment guidelines; for non-covered combination medications, the Member has had a trial of the individual ingredients (or preferred alternatives in the same therapeutic class) when available and covered on the formulary; and trials/failures of formulary alternatives are satisfied as specified below.

    Plan may use prescription claim records to verify maintenance or trials/failures; provider must supply names, strengths, and specifics of failures

    Formulary alternative trial and other approval bases: Approval may be granted if ANY of the following apply: Member has tried and failed at least 2 covered alternatives (or 1 if only one formulary alternative exists for the diagnosis); unable to switch due to specified clinical reasons (e.g., narrow therapeutic index) with documentation; requested because of a drug supply shortage; or brand requested after failure of the interchangeable generic when the generic is a formulary alternative.

    Documentation required to support clinical reasons preventing trial or demonstrating failure; must provide names and strengths of alternatives tried and specifics regarding treatment failure

    This policy defines formulary exception and non-covered drug coverage for BCBSMA commercial members under the BCBSMA formulary and does NOT apply to Medicare Advantage members.

    The policy identifies multiple therapeutic categories and product classes that are listed as non-covered under the pharmacy benefit, including but not limited to: atypical antidepressants and antipsychotics; benzodiazepines and hypnotics; pain/opioid and topical analgesic agents; stimulants, SNRIs, SSRIs, tricyclic antidepressants; cardiovascular classes (ARB, ACEI, beta blockers, CCBs, combinations); HMG-CoA (statins) and combinations; dermatologic topical products and kits; diabetic supplies and insulins; osteoporosis agents; GI agents and bowel preps; and proton pump inhibitors (PPI) for members ≥ 18 years.

    Specific branded and generic products listed as non-covered in this segment include examples such as hyaluronic acid joint replacements (e.g., Durolane, Euflexxa, Gel-One, Hyalgan, Monovisc, Orthovisc, Supartz, Synvisc), numerous NSAID oral and topical formulations (e.g., Voltaren, Naprosyn, Pennsaid, Diclofenac gels), a broad range of OB/GYN and estrogen products and contraceptives, extensive prenatal vitamin brands, ophthalmic anti-infectives and ophthalmic agents (e.g., AzaSite, Besivance, Tobradex, Vigamox, Acular, Restasis), phosphate binder Auryxia, many branded respiratory inhalers and inhaled steroids (e.g., Breo Ellipta, Symbicort, ProAir, Flovent, Arnuity Ellipta), leukotriene modifiers (e.g., Singulair, Accolate, Zyflo), vitamins/minerals, and weight‑loss agents including liraglutide and Zepbound vials. This list in chunks 36–43 is presented as the set of products excluded from coverage.

    Per the policy's Other Policy Conditions, products designated as investigational are considered not medically necessary / non‑covered and are excluded from coverage.

    Non-covered Product Coding / Lists

    Non-covered product list (brand/generic names) - Partial list (chunk 36)NDC | brand/genericNot Covered
    DurolaneDurolane
    EuflexxaEuflexxa
    Gel-OneGel-One
    HyalganHyalgan
    HymovisHymovis
    Hymovis OneHymovis One
    MonoviscMonovisc
    OrthoviscOrthovisc
    Sodium Hyaluronate 1%Sodium Hyaluronate 1%
    SupartzSupartz
    1–10 of 72
    1/8
    Non-covered product list (brand/generic names) - Partial list (chunk 37)NDC | brand/genericNot Covered
    fenoprofen 300mgfenoprofen 300mg
    fenoprofen 400mgfenoprofen 400mg
    FlectorFlector
    Flexipak KitFlexipak Kit
    IbupakIbupak
    ibuprofen 300mgibuprofen 300mg
    ibuprofen/famotidineibuprofen/famotidine
    Indocin suspensionIndocin suspension
    Indomethacin 20mgIndomethacin 20mg
    InflathermInflatherm
    1–10 of 52
    1/6
    Non-covered product list (brand/generic names) - Partial list (chunks 38-41)NDC | brand/genericNot Covered
    ActivellaActivella
    AngeliqAngeliq
    BijuvaBijuva
    DuaveeDuavee
    EstraceEstrace
    PrometriumPrometrium
    AddyiAddyi
    BrisdelleBrisdelle
    DivigelDivigel
    ImvexxyImvexxy
    1–10 of 29
    1/3
    Non-covered product list (brand/generic names) - Partial list (chunks 39-41 continued)NDC | brand/genericNot Covered
    OB Complete PetiteOB Complete Petite
    OB CompleteOB Complete
    OB Complete PremierOB Complete Premier
    OB Complete/DHAOB Complete/DHA
    Obstetrx ECObstetrx EC
    Obstetrx Pak DHAObstetrx Pak DHA
    Obstetrx One 38-1-225Obstetrx One 38-1-225
    ObtrexObtrex
    O-Cal PrenatalO-Cal Prenatal
    One Vite 1MG PlusOne Vite 1MG Plus
    1–10 of 13
    1/2
    Non-covered product list (brand/generic names) - Partial list (chunks 40-41 continued)NDC | brand/genericNot Covered
    Prenatal FortePrenatal Forte
    Prenatal Low IronPrenatal Low Iron
    Prenatal PlusPrenatal Plus
    Prenatal+FE 29-1MGPrenatal+FE 29-1MG
    Prenatal-U 106.5-1Prenatal-U 106.5-1
    Prenate EssentialPrenate Essential
    Prenatal PixiePrenatal Pixie
    Prenate AM 1MGPrenate AM 1MG
    Prenate DHAPrenate DHA
    Prenate MiniPrenate Mini
    1–10 of 13
    1/2
    Non-covered product list (brand/generic names) - Ophthalmic and other agents (chunks 39-41)NDC | brand/genericNot Covered
    AzaSiteAzaSite
    BesivanceBesivance
    MoxezaMoxeza
    Tobradex ointmentTobradex ointment
    Tobradex STTobradex ST
    VigamoxVigamox
    ZyletZylet
    ZymaxidZymaxid
    AcularAcular
    Alphagan PAlphagan P
    1–10 of 36
    1/4
    Non-covered product list (brand/generic names) - Phosphate binders, respiratory, inhaled steroids, leukotriene modifiers, vitamins/minerals, weight loss (chunks 42-43)NDC | brand/genericNot Covered
    AuryxiaAuryxia
    TyrvayaTyrvaya
    VyzultaVyzulta
    XelprosXelpros
    AirSupraAirSupra
    ArformoterolArformoterol
    Albuterol Sulfate HFA (Ventolin Authorized Product)Albuterol Sulfate HFA (Ventolin Authorized Product)
    Albuterol Sulfate HFA (ProAir Authorized Product)Albuterol Sulfate HFA (ProAir Authorized Product)
    AirDuo DigiHalerAirDuo DigiHaler
    AirDuo RespiClickAirDuo RespiClick
    1–10 of 54
    1/6

    Prior Authorization, Step Therapy, Documentation, and Denial Risk

    Prior Authorization

    Prior Authorization Required

    Prior Authorization is required for non-formulary and certain formulary drugs covered under the Rx benefit. To request coverage, providers must submit the Formulary Exception/Prior Authorization form by phone, fax, or mail to the Pharmacy Operations Department (see contact below).

    • Submission methods: phone, fax, or mail using the Formulary Exception/Prior Authorization form.
    • Pharmacy Operations Department, Blue Cross Blue Shield of Massachusetts, 25 Technology Place, Hingham, MA 02043.
    Step Therapy

    Step Therapy / Trials Required

    When formulary alternatives exist, step therapy (trial and failure) requirements apply. The member must have tried and failed at least 2 covered alternatives (or 1 if only one formulary alternative exists within the same therapeutic class for the given diagnosis). Document the name and strength of alternatives tried and specifics regarding treatment failure.

    • 2 alternatives required, or 1 if only one formulary alternative is covered in the same therapeutic class.

    Policy Background and Rationale

    BCBSMA maintains a Non‑Covered Drug List to promote clinically appropriate and cost‑effective prescribing when safe, comparably effective, or generic alternatives exist. Individual formulary exceptions and prior authorization reviews may allow coverage when the provider documents successful maintenance on the non‑formulary drug or submits clinical justification demonstrating that switching to a formulary alternative would cause instability; documentation and medication history are required to support such exceptions.

    Key Definitions

    Non-covered drug — definition
    DefinitionA non-covered drug is a medication not covered because safe, comparably effective formulary alternatives or generic versions of the brand-name product are available.
    Coverage implicationDrugs on the non-covered list are not covered under the pharmacy benefit; use or claims for these drugs may be denied and not reimbursed.
    Formulary exception pathwayA non-covered drug may be authorized if the member meets the policy's formulary exception criteria (e.g., successful maintenance documented or other approval bases).
    Alternatives standardAlternatives referenced are FDA‑approved and widely accepted to treat the same condition as the non-covered medication.
    Related program purposeProgram aims to promote clinically appropriate and cost‑effective prescription drug use by requiring formulary alternatives when available.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyFormulary Exception / Non-covered Drug Prior Authorization
    Policy CodePolicy 433
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionSubmit the Formulary Exception/Prior Authorization form to BCBSMA Pharmacy Operations to request coverage for non-formulary or non-covered drugs.
    SourceLink
    On This Page
    Formulary Exception and Non-covered Drug Coverage CriteriaNon-covered Product Coding / ListsPrior Authorization, Step Therapy, Documentation, and Denial RiskPolicy Background and RationaleKey Definitions
  1. Reasons for failure: inadequate treatment response, intolerance, contraindication, allergic/adverse reaction.
  2. Documentation Required

    Required Provider Documentation

    Providers must supply clinical documentation to support exceptions or prior authorization requests. Acceptable documentation includes clinical notes, medication history, prescription claim records, and specifics about treatment failure or clinical justification for not switching to a formulary alternative.

    • Include name and strength of alternatives tried and failed and specifics regarding treatment failure when applicable.
    • Include clinical notes or supporting clinical statements and any relevant peer-reviewed literature or compendia references for individual consideration.
    • Prescription claim records may be used by the plan; provide additional information if historic claim data is unavailable or insufficient.
    Note

    Non-covered Drugs — Prior Authorization Not Applicable

    Drugs listed on the Non-covered Drug List are not eligible for coverage via prior authorization or exception under the pharmacy benefit unless explicitly stated elsewhere in policy. Prior authorization is not applicable to items on the Non-covered Drug List.

    • Non-covered lists appear in the policy and include, but are not limited to, specified branded and generic products across therapeutic classes.
    • Claims or requests for listed non-covered drugs will not be converted to covered via PA unless policy explicitly indicates otherwise.
    Denial Risk

    Denial Risk for Insufficient Documentation

    Requests may be denied if submitted documentation does not demonstrate required clinical justification, successful maintenance, or trial-and-failure of formulary alternatives when applicable. Ensure documentation clearly shows why alternatives are inappropriate or why switching would cause instability.

    • Denials may occur for insufficient documentation of treatment failure, lack of medication history, or missing clinical rationale.
    • Provide specific details (names/strengths/dates of trials, clinical course) to reduce denial risk.
    Denial Risk

    Denial Risk for Non-covered Drugs

    Claims for drugs listed on the Non-covered Drug List will be denied under the pharmacy benefit and are not reimbursable. Inclusion on the Non-covered Drug List is an explicit exclusion from coverage unless another policy section states otherwise.

    • Providers should verify whether a drug appears on the Non-covered Drug List before submitting a request.
    • Denials for non-covered items will not be overturned by standard prior authorization processes; individual consideration exceptions may be considered only where policy permits and supporting documentation justifies.
    • Use the Non-covered Drug List as a reference when preparing documentation.
    Successful maintenance — definition
    Successful maintenance — definitionEstablished when the provider documents, via clinical records or medication history, that the member has been successfully maintained on the current medication regimen and that switching to a formulary alternative would result in instability of the medical condition.
    Documentation requiredProvider must supply clinical records or medication history supporting the clinical justification that a change would cause instability.
    Evidence sourcesPrescription claim records or clinical notes may be used to verify maintenance and support the exception request.
    Approval durationIf authorized based on maintenance, length of approval is 24 months.
    Use in decision-makingSuccessful maintenance is one primary coverage pathway to determine medical necessity for otherwise non-covered drugs.